की कीमत क्या है Autolus Therapeutics plc (AUTL)

का मूल्य Autolus Therapeutics plc (AUTL) है $2.34

का बाजार पूंजीकरण क्या है Autolus Therapeutics plc (AUTL)

का बाजार पूंजीकरण Autolus Therapeutics plc (AUTL) है $621.44M

Autolus Therapeutics plc (AUTL) प्रति शेयर आय

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

वर्ष	EPS	परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

वर्ष

EPS

परिवर्तन

प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

कंपनी	EPS	EPS अंतर	देश
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
CSL Limited CSL.AX	$-5.29	-	AU
Moderna, Inc. MRNA.US	$-7.98	-	US
Lonza Group AG LONN.SW	-	-	CH

कंपनी

EPS

EPS अंतर

देश